Treatment of mice bearing poorly immunogenic B16 tumors with co-administration of S100, anti-PD-1, and anti-CTLA-4 yielded significant increases in IFN-γ-secreting tumor-specific T cells and conferred a significant survival benefit over mice receiving single-agent regimens (136). The gene discussed is CTLA4; the disease is neoplasm.